DE-117 ophthalmic solution
Sponsors
Santen Inc., Santen Pharmaceutical Co., Ltd.
Conditions
Glaucoma and Ocular HypertensionOpen Angle Glaucoma or Ocular HypertensionOpen-angle Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma or Ocular HypertensionPrimary Open-angle Glaucoma and Ocular Hypertension
Phase 2
Phase 3
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
CompletedNCT02822729
Start: 2016-07-01End: 2017-11-09Updated: 2017-11-20
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
CompletedNCT02822742
Start: 2016-07-02End: 2017-04-28Updated: 2017-11-20
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
CompletedNCT03691662
Start: 2018-09-27End: 2019-10-23Updated: 2023-08-09
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
CompletedNCT03691649
Start: 2018-09-14End: 2020-09-03Updated: 2023-08-30
DE-117 Spectrum 5 Study
CompletedNCT03697811
Start: 2018-09-27End: 2022-01-13Updated: 2023-08-30